Hillstream BioPharma, Inc. (HILS)
Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers.
The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.
The company was incorporated in 2017 and is based in Bridgewater, New Jersey.
|IPO Date||Jan 12, 2022|
|CEO||Mr. Randy D. Milby MBA|
1200 Route 22 East
Bridgewater, New Jersey 08807
|Fiscal Year||January - December|
|Randy D. Milby MBA||President, Chairman and Chief Executive Officer|
|Thomas P. Hess CPA, MBA||Chief Financial Officer|
Latest SEC Filings
|Nov 14, 2022||10-Q||Quarterly Report|
|Oct 28, 2022||8-K||Current Report|
|Aug 11, 2022||10-Q||Quarterly Report|
|Aug 9, 2022||8-K||Current Report|
|Jun 23, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Jun 17, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Jun 17, 2022||DEF 14A||Other definitive proxy statements|
|May 16, 2022||10-Q||Quarterly Report|
|Apr 1, 2022||10-K||Annual Report|
|Apr 1, 2022||NT 10-K||Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405|